Nanion Corporate Blog


12.04.2019: Assessing cardiotoxic risk of anti-cancer agents on Nanion's CardioExcyte 96

Learn how new anti-cancer agents have led to higher life expectancy for cancer surviving patients, why cardiotoxic side effects such as arrhythmia, thromboembolism and myocardial ischemia are common with anti-cancer drugs such as the anthracyclines and to what degree can advances in human stem cell derived cardiomyocytes (hiPSC-CMs) and patient-derived hiPSC-CMs offer new possibilities for personalized medicine. Read the Application Note here.

Additionally, don’t miss out on Nanion Technologies Newsbites by Signing Up for free here.

Back to Overview

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.